The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
ALS patients experience neuroinflammation and rapid neurodegeneration
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
Subscribe To Our Newsletter & Stay Updated
